$RGLS
Regulus Therapeutics Inc.

2015 Q2 Form 10-Q Financial Statement

#000119312515276880 Filed on August 05, 2015

View on sec.gov

Income Statement

Concept 2015 Q2 2014 Q2
Revenue $3.834M $736.0K
YoY Change 420.92% -84.53%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $5.810M $2.950M
YoY Change 96.95% 71.51%
% of Gross Profit
Research & Development $19.20M $10.80M
YoY Change 77.87% 39.8%
% of Gross Profit
Depreciation & Amortization $410.0K $350.0K
YoY Change 17.14% 2.94%
% of Gross Profit
Operating Expenses $25.02M $13.75M
YoY Change 81.94% 45.57%
Operating Profit -$21.18M -$13.01M
YoY Change 62.77% 177.7%
Interest Expense $7.000K $10.00K
YoY Change -30.0% -44.44%
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income -$21.04M -$11.97M
YoY Change 75.7% 63.16%
Income Tax -$2.000K $0.00
% Of Pretax Income
Net Earnings -$21.04M -$11.97M
YoY Change 75.69% 62.94%
Net Earnings / Revenue -548.64% -1626.77%
Basic Earnings Per Share -$0.41 -$0.28
Diluted Earnings Per Share -$0.41 -$0.29
COMMON SHARES
Basic Shares Outstanding 51.07M shares 43.36M shares
Diluted Shares Outstanding 51.07M shares 44.80M shares

Balance Sheet

Concept 2015 Q2 2014 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $139.4M $103.5M
YoY Change 34.69% 25.15%
Cash & Equivalents $21.08M $10.02M
Short-Term Investments $118.3M $93.50M
Other Short-Term Assets $4.100M $4.400M
YoY Change -6.82% 175.0%
Inventory
Prepaid Expenses
Receivables $600.0K
Other Receivables $0.00
Total Short-Term Assets $144.1M $107.9M
YoY Change 33.56% 24.19%
LONG-TERM ASSETS
Property, Plant & Equipment $3.310M $3.948M
YoY Change -16.16% -1.57%
Goodwill
YoY Change
Intangibles $1.072M $1.112M
YoY Change -3.6% -9.52%
Long-Term Investments
YoY Change
Other Assets $1.794M $977.0K
YoY Change 83.62% 141.83%
Total Long-Term Assets $6.176M $6.037M
YoY Change 2.3% 6.96%
TOTAL ASSETS
Total Short-Term Assets $144.1M $107.9M
Total Long-Term Assets $6.176M $6.037M
Total Assets $150.3M $113.9M
YoY Change 31.9% 23.14%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $2.407M $3.018M
YoY Change -20.25% 193.58%
Accrued Expenses $6.834M $4.432M
YoY Change 54.2% 112.97%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due $0.00
YoY Change
Total Short-Term Liabilities $14.55M $11.27M
YoY Change 29.11% -40.72%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $12.50M
YoY Change -100.0% -14.38%
Other Long-Term Liabilities $804.0K $1.260M
YoY Change -36.19% -28.61%
Total Long-Term Liabilities $804.0K $1.260M
YoY Change -36.19% -28.61%
TOTAL LIABILITIES
Total Short-Term Liabilities $14.55M $11.27M
Total Long-Term Liabilities $804.0K $1.260M
Total Liabilities $17.64M $31.84M
YoY Change -44.6% -26.29%
SHAREHOLDERS EQUITY
Retained Earnings -$171.3M -$103.8M
YoY Change 65.02% 38.41%
Common Stock $304.1M $43.00K
YoY Change 707041.86% 19.44%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $132.6M $82.08M
YoY Change
Total Liabilities & Shareholders Equity $150.3M $113.9M
YoY Change 31.9% 23.14%

Cashflow Statement

Concept 2015 Q2 2014 Q2
OPERATING ACTIVITIES
Net Income -$21.04M -$11.97M
YoY Change 75.69% 62.94%
Depreciation, Depletion And Amortization $410.0K $350.0K
YoY Change 17.14% 2.94%
Cash From Operating Activities -$9.770M -$10.02M
YoY Change -2.5% 34.86%
INVESTING ACTIVITIES
Capital Expenditures -$170.0K -$650.0K
YoY Change -73.85% 242.11%
Acquisitions
YoY Change
Other Investing Activities $10.50M $12.20M
YoY Change -13.93% 36.92%
Cash From Investing Activities $10.33M $11.53M
YoY Change -10.41% 32.22%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 920.0K 30.00K
YoY Change 2966.67% -50.0%
NET CHANGE
Cash From Operating Activities -9.770M -10.02M
Cash From Investing Activities 10.33M 11.53M
Cash From Financing Activities 920.0K 30.00K
Net Change In Cash 1.480M 1.540M
YoY Change -3.9% 14.07%
FREE CASH FLOW
Cash From Operating Activities -$9.770M -$10.02M
Capital Expenditures -$170.0K -$650.0K
Free Cash Flow -$9.600M -$9.370M
YoY Change 2.45% 29.42%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2015Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
51919532 shares
CY2014Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
10024000
CY2015Q2 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
9028868 shares
CY2015Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
6064456 shares
CY2015Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2015Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
1672578 shares
CY2015Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000 shares
CY2015Q2 us-gaap Debt Instrument Convertible Conversion Price1
DebtInstrumentConvertibleConversionPrice1
4.00
CY2015Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
51533416 shares
CY2015Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
8.71
CY2015Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
51533416 shares
CY2015Q2 us-gaap Liabilities Current
LiabilitiesCurrent
14547000
CY2015Q2 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
2274000
CY2015Q2 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
2287000
CY2015Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
6834000
CY2015Q2 us-gaap Liabilities
Liabilities
17638000
CY2015Q2 us-gaap Common Stock Value
CommonStockValue
52000
CY2015Q2 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
304019000
CY2015Q2 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
804000
CY2015Q2 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
3032000
CY2015Q2 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-155000
CY2015Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-171289000
CY2015Q2 us-gaap Stockholders Equity
StockholdersEquity
132627000
CY2015Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
150265000
CY2015Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
2407000
CY2015Q2 us-gaap Assets Fair Value Disclosure Recurring
AssetsFairValueDisclosureRecurring
137862000
CY2015Q2 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
1072000
CY2015Q2 us-gaap Accounts And Other Receivables Net Current
AccountsAndOtherReceivablesNetCurrent
616000
CY2015Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
3310000
CY2015Q2 us-gaap Assets Current
AssetsCurrent
144089000
CY2015Q2 us-gaap Short Term Investments
ShortTermInvestments
118284000
CY2015Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
21084000
CY2015Q2 us-gaap Assets
Assets
150265000
CY2015Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
4105000
CY2015Q2 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
1794000
CY2015Q2 rgls Short Term Investments Amortized Cost
ShortTermInvestmentsAmortizedCost
118392000
CY2013Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
17807000
CY2014Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
6643000 shares
CY2014Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2014Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000 shares
CY2014Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
48944530 shares
CY2014Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
6.95
CY2014Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
48944530 shares
CY2014Q4 us-gaap Liabilities Current
LiabilitiesCurrent
35192000
CY2014Q4 us-gaap Short Term Investments
ShortTermInvestments
122416000
CY2014Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
2108000
CY2014Q4 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
3252000
CY2014Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
4402000
CY2014Q4 us-gaap Liabilities
Liabilities
39466000
CY2014Q4 us-gaap Common Stock Value
CommonStockValue
49000
CY2014Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
267929000
CY2014Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
1022000
CY2014Q4 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
3097000
CY2014Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-197000
CY2014Q4 us-gaap Convertible Notes Payable Current
ConvertibleNotesPayableCurrent
23397000
CY2014Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-135767000
CY2014Q4 us-gaap Stockholders Equity
StockholdersEquity
132014000
CY2014Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
171480000
CY2014Q4 us-gaap Convertible Debt Fair Value Disclosures
ConvertibleDebtFairValueDisclosures
23400000
CY2014Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
2188000
CY2014Q4 us-gaap Assets Fair Value Disclosure Recurring
AssetsFairValueDisclosureRecurring
159488000
CY2014Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
1150000
CY2014Q4 us-gaap Accounts And Other Receivables Net Current
AccountsAndOtherReceivablesNetCurrent
274000
CY2014Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
3568000
CY2014Q4 us-gaap Assets Current
AssetsCurrent
164951000
CY2014Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
37327000
CY2014Q4 us-gaap Assets
Assets
171480000
CY2014Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
4934000
CY2014Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
1811000
CY2014Q4 rgls Short Term Investments Amortized Cost
ShortTermInvestmentsAmortizedCost
122580000
CY2015Q1 us-gaap Debt Instrument Convertible Conversion Price1
DebtInstrumentConvertibleConversionPrice1
4.00
CY2015Q1 us-gaap Share Price
SharePrice
18.58
CY2015Q1 us-gaap Debt Conversion Converted Instrument Shares Issued1
DebtConversionConvertedInstrumentSharesIssued1
1356738 shares
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
4044298 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
43028198 shares
us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-19051000
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.57
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
43028198 shares
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.57
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-24740000
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
117000
us-gaap Repayments Of Other Long Term Debt
RepaymentsOfOtherLongTermDebt
70000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
731000
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
-876000
us-gaap Operating Income Loss
OperatingIncomeLoss
-23718000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-24713000
us-gaap Gain Loss On Disposition Of Assets
GainLossOnDispositionOfAssets
-18000
us-gaap Revenues
Revenues
2367000
us-gaap Interest And Other Income
InterestAndOtherIncome
197000
us-gaap Nonoperating Gains Losses
NonoperatingGainsLosses
-1171000
us-gaap Interest Paid
InterestPaid
21000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
1197000
us-gaap Payments To Acquire Short Term Investments
PaymentsToAcquireShortTermInvestments
48301000
us-gaap Net Income Loss
NetIncomeLoss
-24714000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-26000
us-gaap Payments To Acquire Intangible Assets
PaymentsToAcquireIntangibleAssets
34000
us-gaap Income Taxes Paid
IncomeTaxesPaid
1000
us-gaap Interest Expense
InterestExpense
21000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
9728000
us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
-109000
us-gaap Operating Expenses
OperatingExpenses
26085000
us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
10214000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
700000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-1000
us-gaap Increase Decrease In Deferred Liabilities
IncreaseDecreaseInDeferredLiabilities
-124000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
5686000
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-1896000
us-gaap Proceeds From Sale Maturity And Collection Of Shortterm Investments
ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments
50120000
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-7783000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
3083000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
1729000
us-gaap Share Based Compensation
ShareBasedCompensation
3083000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
1412000
us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
1054000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
556000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
20399000
dei Document Type
DocumentType
10-Q
dei Trading Symbol
TradingSymbol
RGLS
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
1141000 shares
dei Entity Central Index Key
EntityCentralIndexKey
0001505512
dei Document Period End Date
DocumentPeriodEndDate
2015-06-30
dei Entity Filer Category
EntityFilerCategory
Accelerated Filer
us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-21015000
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
3331699 shares
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
11.32
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
12.50
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
50575096 shares
dei Amendment Flag
AmendmentFlag
false
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
514000 shares
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
1.48
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
1206000 shares
dei Entity Registrant Name
EntityRegistrantName
REGULUS THERAPEUTICS INC.
us-gaap Debt Instrument Maturity Date
DebtInstrumentMaturityDate
2015-10-09
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.70
us-gaap Use Of Estimates
UseOfEstimates
<div> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"> <b>Use of Estimates</b></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"> Our condensed financial statements are prepared in accordance with GAAP, which requires us to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses and the disclosure of contingent assets and liabilities in our financial statements and accompanying notes. Although these estimates are based on our knowledge of current events and actions we may undertake in the future, actual results may ultimately differ from these estimates and assumptions.</p> </div>
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2015
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
50575096 shares
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.70
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-35467000
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
90000
us-gaap Repayments Of Other Long Term Debt
RepaymentsOfOtherLongTermDebt
75000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
410000
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
-801000
us-gaap Operating Income Loss
OperatingIncomeLoss
-34052000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-35528000
us-gaap Gain Loss On Disposition Of Assets
GainLossOnDispositionOfAssets
-56000
us-gaap Interest And Other Income
InterestAndOtherIncome
351000
us-gaap Revenues
Revenues
8034000
us-gaap Nonoperating Gains Losses
NonoperatingGainsLosses
-1811000
us-gaap Interest Paid
InterestPaid
15000
us-gaap Increase Decrease In Accounts And Other Receivables
IncreaseDecreaseInAccountsAndOtherReceivables
50000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-846000
us-gaap Payments To Acquire Short Term Investments
PaymentsToAcquireShortTermInvestments
46281000
us-gaap Net Income Loss
NetIncomeLoss
-35522000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
55000
us-gaap Payments To Acquire Intangible Assets
PaymentsToAcquireIntangibleAssets
19000
us-gaap Income Taxes Paid
IncomeTaxesPaid
1000
us-gaap Unrealized Gain On Securities
UnrealizedGainOnSecurities
6000
us-gaap Interest Expense
InterestExpense
16000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
257000
us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
167000
us-gaap Operating Expenses
OperatingExpenses
42086000
us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
1837000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
798000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
6000
us-gaap Increase Decrease In Deferred Liabilities
IncreaseDecreaseInDeferredLiabilities
-160000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
9458000
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-1323000
us-gaap Proceeds From Sale Maturity And Collection Of Shortterm Investments
ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments
49645000
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-16243000
us-gaap Unrealized Loss On Securities
UnrealizedLossOnSecurities
114000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
8972000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
130000
us-gaap Share Based Compensation
ShareBasedCompensation
8972000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
2459000
us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
2935000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
1655000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
32628000
CY2014 us-gaap Fair Value Assumptions Risk Free Interest Rate
FairValueAssumptionsRiskFreeInterestRate
0.0010 pure
CY2014 us-gaap Fair Value Inputs Entity Credit Risk
FairValueInputsEntityCreditRisk
0.097 pure
CY2014 us-gaap Fair Value Assumptions Weighted Average Volatility Rate
FairValueAssumptionsWeightedAverageVolatilityRate
1.10 pure
CY2014 us-gaap Unrealized Gain On Securities
UnrealizedGainOnSecurities
3000
CY2014 us-gaap Unrealized Loss On Securities
UnrealizedLossOnSecurities
167000
CY2014Q2 us-gaap Incremental Common Shares Attributable To Conversion Of Debt Securities
IncrementalCommonSharesAttributableToConversionOfDebtSecurities
1437053 shares
CY2014Q2 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
2052638 shares
CY2014Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
43362483 shares
CY2014Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.28
CY2014Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
44799536 shares
CY2014Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.29
CY2014Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-11956000
CY2014Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-13013000
CY2014Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-11973000
CY2014Q2 us-gaap Interest And Other Income
InterestAndOtherIncome
97000
CY2014Q2 us-gaap Revenues
Revenues
736000
CY2014Q2 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-12926000
CY2014Q2 us-gaap Nonoperating Gains Losses
NonoperatingGainsLosses
953000
CY2014Q2 us-gaap Net Income Loss
NetIncomeLoss
-11973000
CY2014Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
17000
CY2014Q2 us-gaap Interest Expense
InterestExpense
10000
CY2014Q2 us-gaap Operating Expenses
OperatingExpenses
13749000
CY2014Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2954000
CY2014Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1684000
CY2014Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
10795000
CY2015Q2 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
2905340 shares
CY2015Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
51073488 shares
CY2015Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.41
CY2015Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
51073488 shares
CY2015Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.41
CY2015Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-21037000
CY2015Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-21181000
CY2015Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-21037000
CY2015Q2 us-gaap Interest And Other Income
InterestAndOtherIncome
151000
CY2015Q2 us-gaap Revenues
Revenues
3834000
CY2015Q2 us-gaap Nonoperating Gains Losses
NonoperatingGainsLosses
0
CY2015Q2 us-gaap Net Income Loss
NetIncomeLoss
-21035000
CY2015Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-2000
CY2015Q2 us-gaap Interest Expense
InterestExpense
7000
CY2015Q2 us-gaap Operating Expenses
OperatingExpenses
25015000
CY2015Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
2000
CY2015Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
5814000
CY2015Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
5869000
CY2015Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
19201000

Files In Submission

Name View Source Status
0001193125-15-276880-index-headers.html Edgar Link pending
0001193125-15-276880-index.html Edgar Link pending
0001193125-15-276880.txt Edgar Link pending
0001193125-15-276880-xbrl.zip Edgar Link pending
d938318d10q.htm Edgar Link pending
d938318dex101.htm Edgar Link pending
d938318dex102.htm Edgar Link pending
d938318dex311.htm Edgar Link pending
d938318dex312.htm Edgar Link pending
d938318dex321.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
g938318g22k85.jpg Edgar Link pending
g938318g67h96.jpg Edgar Link pending
g938318g87k52.jpg Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
rgls-20150630.xml Edgar Link completed
rgls-20150630.xsd Edgar Link pending
rgls-20150630_cal.xml Edgar Link unprocessable
rgls-20150630_def.xml Edgar Link unprocessable
rgls-20150630_lab.xml Edgar Link unprocessable
rgls-20150630_pre.xml Edgar Link unprocessable
Show.js Edgar Link pending